Intravesical mitoxantrone in superficial bladder cancer

Area of Science:

• Urology
• Oncology
• Pharmacology

Background:

• Transitional cell carcinoma (TCC) of the bladder, particularly stages Ta-T1, has a significant risk of recurrence.
• Adjuvant intravesical therapies are crucial for preventing tumor relapse after initial treatment.
• Current chemoprophylaxis options have varying efficacy and tolerability profiles.

Purpose of the Study:

• To evaluate the efficacy and safety of intravesical mitoxantrone as a chemoprophylactic agent for non-muscle-invasive bladder cancer.
• To compare the relapse-free rates in patients receiving mitoxantrone with historical data for other intravesical agents.

Main Methods:

• A prospective study involving 25 patients diagnosed with Ta-T1 TCC of the bladder.
• Treatment consisted of transurethral resection (TUR) followed by weekly intravesical instillations of mitoxantrone (10 mg in 50 ml saline) for six weeks.
• Patients were followed for a mean duration of 12 months to assess recurrence rates and toxicity.

Main Results:

• An overall relapse-free survival rate of 76% was observed at 12 months.
• Relapse-free rates were 69% for newly diagnosed patients and 89% for previously relapsed patients.
• The treatment was generally well-tolerated, with only two patients experiencing grade 3 local toxicity.

Conclusions:

• Intravesical mitoxantrone demonstrates significant efficacy in preventing recurrence of Ta-T1 bladder transitional cell carcinoma.
• Mitoxantrone offers a favorable safety profile, with manageable local toxicity.
• This agent presents a promising alternative for intravesical chemoprophylaxis in non-muscle-invasive bladder cancer.